Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face (ImiReduc)

This study is currently recruiting participants.
Verified July 2013 by Nantes University Hospital
Sponsor:
Collaborator:
MEDA Pharma GmbH & Co. KG
Information provided by (Responsible Party):
Nantes University Hospital
ClinicalTrials.gov Identifier:
NCT01720407
First received: October 23, 2012
Last updated: July 10, 2013
Last verified: July 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)